-
GlaxoSmithKline says five late-stage trials meet main goal
Oct 22, 12 Clinical UpdatesGlaxoSmithKline Plc said results from five late-stage trials of two experimental quadrivalent influenza vaccines (QIV) met the main goal of protecting against mild as well as moderate-severe cases of influenza.
GSK said its experimental vaccines contain two influenza A strains and two influenza B strains to potentially help broaden protection against seasonal influenza, compared to approved trivalent vaccines that contain two A influenza strains and one B influenza strain.
(Reporting by Monika Shinghal in Bangalore)
###
(Reuters)Also in this section:
Subscribe to the "News" RSS Feed 
TOP ۞
